Anti-TRAIL antibody [2E5] (ab2219)
Key features and details
- Mouse monoclonal [2E5] to TRAIL
- Suitable for: Functional Studies
- Reacts with: Human
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
Anti-TRAIL antibody [2E5]
See all TRAIL primary antibodies -
Description
Mouse monoclonal [2E5] to TRAIL -
Host species
Mouse -
Specificity
This antibody is specific for TRAIL, Tumour necrosis factor (TNF) related apoptosis inducing ligand (TRAIL/ APO2-L)).
-
Tested applications
Suitable for: Functional Studiesmore details -
Species reactivity
Reacts with: Human
Does not react with: Mouse -
Immunogen
Recombinant soluble fragment, corresponding to amino acids 95-281 of Human TRAIL.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Protein A purified -
Purification notes
Purified from TCS. -
Clonality
Monoclonal -
Clone number
2E5 -
Myeloma
unknown -
Isotype
IgG1 -
Light chain type
unknown -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab2219 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. |
Notes |
---|
Functional Studies
Use at an assay dependent concentration. The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. |
Target
-
Function
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. -
Tissue specificity
Widespread; most predominant in spleen, lung and prostate. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8743 Human
- Omim: 603598 Human
- SwissProt: P50591 Human
- Unigene: 478275 Human
-
Alternative names
- Apo 2 ligand antibody
- APO 2L antibody
- Apo-2 ligand antibody
see all
Images
-
Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5).
The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL.
A - medium
B - recombinant TRAIL
C - recombinant TRAIL + anti-human TRAIL (2E5; 0.06 µg/ml)
D - recombinant TRAIL + anti-human TRAIL (2E5; 0.24 µg/ml)
E - recombinant TRAIL + Isotype mouse IgG1 control
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (6)
ab2219 has been referenced in 6 publications.
- Nordmaj MA et al. Development of a bispecific immune engager using a recombinant malaria protein. Cell Death Dis 12:353 (2021). PubMed: 33824272
- Tatzel K et al. Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. Sci Rep 6:22661 (2016). Flow Cyt . PubMed: 26935795
- Yunker PJ et al. One-pot system for synthesis, assembly, and display of functional single-span membrane proteins on oil-water interfaces. Proc Natl Acad Sci U S A 113:608-13 (2016). PubMed: 26721399
- Sharova TY et al. Complex Changes in the Apoptotic and Cell Differentiation Programs during Initiation of the Hair Follicle Response to Chemotherapy. J Invest Dermatol N/A:N/A (2014). PubMed: 24999588
- Hyer ML et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799-808 (2005). PubMed: 15930300
- Plasilova M et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16:67-73 (2002). PubMed: 11840265